Fused Indole Allosteric Modulators for Oxytocin Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting the oxytocin receptor (OTR) lack effective allosteric modulators that can selectively modulate oxytocin activity, leading to non-specific activation of vasopressin receptors and poor stability of oxytocin, which limits their therapeutic efficacy in treating social and neuropsychiatric disorders.
Innovation Solution
Development of fused indole compounds that bind allosterically to the oxytocin receptor, modulating its activity through specific interaction, potentially offering improved selectivity and stability compared to traditional orthosteric ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orthosteric ligands are used to target the oxytocin receptor, then the receptor can be activated, but selectivity between OTR and vasopressin receptors is compromised due to structural similarity of endogenous ligands
Solution Approach 1:
The patent introduces an allosteric modulator as an intermediary compound that indirectly influences the oxytocin receptor activity. Instead of directly competing for the orthosteric site (which causes cross-reactivity with vasopressin receptors), the allosteric modulator binds to a distinct site on the OTR and modulates its function, thereby achieving selective modulation without activating vasopressin receptors.
Solution Approach 2:
The invention targets a specific local site on the oxytocin receptor - the allosteric site - rather than the general orthosteric binding site. This localized approach allows the compound to exert its effect specifically on OTR conformation and activity without affecting other receptors that share the orthosteric binding characteristics.
2Reliability
If traditional orthosteric inhibitors are developed, then OTR can be targeted, but stability and therapeutic efficacy are limited
Solution Approach 1:
The allosteric modulator serves as a stable intermediary compound that does not suffer from the same stability issues as endogenous oxytocin. By binding to a different site on the receptor, the compound achieves prolonged receptor modulation without the rapid degradation that plagues orthosteric oxytocin-based therapies.
3Reliability
If allosteric binding is implemented, then selectivity and stability are improved, but the mechanism of action becomes more complex to characterize
Solution Approach 1:
While the allosteric mechanism is indeed more complex than simple orthosteric competition, the patent provides a clear mechanistic framework: the compound binds to an allosteric site, induces conformational changes in the receptor, and modulates oxytocin binding or receptor activation. This intermediary mechanism, though complex, offers superior selectivity and stability profiles.
Data Source
AI summary
This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to modulate the activity of oxytocin at the oxytocin receptor.